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Abstract
Background: Pseudomonas aeruginosa infections are associated with progressive life threatening decline of lung
function in cystic fibrosis sufferers. Growth of Ps. aeruginosa releases a “grape-like” odour that has been identified
as the microbial volatile organic compound 2-aminoacetophenone (2-AA).
Methods: We investigated 2-AA for its specificity to Ps. aeruginosa and its suitability as a potential breath
biomarker of colonisation or infection by Solid Phase Micro Extraction and Gas Chromatography-Mass Spectrometry
(GC/MS).
Results: Cultures of 20 clinical strains of Ps. aeruginosa but not other respiratory pathogens had high concentrations
of 2-AA in the head space of in vitro cultures when analysed by GC/MS. 2-AA was stable for 6 hours in deactivated
glass sampling bulbs but was not stable in Tedlar® bags. Optimisation of GC/MS allowed detection levels of 2-AA to
low pico mol/mol range in breath. The 2-AA was detected in a significantly higher proportion of subjects colonised
with Ps. aeruginosa 15/16 (93.7%) than both the healthy controls 5/17 (29%) (p < 0.0002) and CF patients not
colonised with Ps. aeruginosa 4/13(30.7%) (p < 0.001). The sensitivity and specificity of the 2-AA breath test compared
to isolation of Ps. aeruginosa in sputum and/or BALF was 93.8% (95% CI, 67-99) and 69.2% (95% CI, 38-89)
respectively. The peak integration values for 2-AA analysis in the breath samples were significantly higher in
Ps. aeruginosa colonised subjects (median 242, range 0-1243) than the healthy controls (median 0, range 0-161;
p < 0.001) and CF subjects not colonised with Ps. aeruginosa (median 0, range 0-287; p < 0.003)
Conclusions: Our results report 2-AA as a promising breath biomarker for the detection of Ps. aeruginosa infections
in the cystic fibrosis lung.
Background
Pseudomonas aeruginosa is a Gram negative bacterium
that produces a sweet “grape-like” odour during
growth. In 1966 Mann [1] identified this compound as
2-aminoacetophenone (2-AA) by thin-layer chromato-
graphy. Cox & Parker [2] confirmed 2-AA as the com-
pound responsible for this odour and we have also
successfully detected and identified 2-AA in the head-
space of in vitro cultures using gas chromatography/
mass spectrometry (GC/MS) (Figure 1). 2-Aminoace-
tophenone is a small, volatile aromatic compound
with a molecular weight of 135 g/mol (Figure 1). It is
an intermediate product in the biosynthesis of quina-
zolines, which branches from the tryptophan catabolic
pathway [3]. 2-Aminoacetophenone is consistently
produced by multiple Ps. aeruginosa strains, on all
culture media, and is a major metabolite [2-4], but the
biological significance of this compound is unknown
[2]. There is a single report of 2-AA detected in the
headspace of Escherichia coli cultures [5] but 2-AA is
not known to be produced by other respiratory patho-
gens. Because of the well described evidence of the
production of 2-AA by Ps. aeruginosa and its apparent
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biomarker for infection and/or colonisation of the
lung.
Cystic Fibrosis (CF) is an autosomal recessive disease
affecting 1 in 3300 live Caucasian births [6]. The secre-
tion of hyperviscous mucus in the CF-affected lung pro-
vides Ps. aeruginosa with a nutritionally rich growth
environment, where it often grows to high cell densities
(>10
9 cells/ml sputum) [7,8]. Although many other bac-
terial species persist and grow in the CF lung, chronic
Ps. aeruginosa infection correlates with declining lung
function and high mortality rates [4,9].
None of the current methods for detecting Ps. aerugi-
nosa infections in CF patients are satisfactory. The cul-
ture of broncho-alveolar lavage fluid (BALF) is currently
the reference standard for lower respiratory tract coloni-
sation and infection [10]. However, this procedure is
invasive and requires general anaesthetic in the very
young. While BALF is not routinely performed, it has
been used successfully in screening studies of both
newly diagnosed and very young CF patients [11,12].
Cultures of sputum samples are significantly less sensi-
tive than BALF [13] and cultures of the oropharynx
have poor sensitivity and do not reliably predict the pre-
sence of organisms in the lower airways [14].
We have therefore undertaken an investigation to
determine whether 2-AA is consistently produced by
Ps. aeruginosa and other respiratory pathogens during
in vitro culture and if 2-AA is detectable in the breath
of CF patients colonised with Ps. aeruginosa.
Methods
Materials
2-Aminoacetophenone, hexamethyldisilazane and 1 L
glass sampling bulbs were purchased from Sigma
Aldrich, St. Louis, Missouri, United States of America.
2 L Tedlar® bags were purchased from SKC Inc., PA,
USA. Vials of tobramycin (Hospira, Wellington, New
Zealand) and colistin (Link, Australia) for clinical use
were obtained from the Christchurch Hospital Phar-
macy, New Zealand.
Solid Phase Micro Extraction
SPME fibres (60 μm Carbowax™/PEG) (Supelco,
Bellefonte, Pennsylvania, United States of America) were
used to pre-concentrate 2-AA from the headspace of
cultures and breath samples. Each SPME fibre was pre-
conditioned in a hot injector at 250°C, a test chromato-
gram was recorded and the clean and activated fibre
was then exposed into the sample headspace.
Detection of 2-AA by GC/MS
A Saturn 2200 system (Varian, Palo Alto, USA) was
used to perform the GC/MS analysis. A Zebron ZB-
Wax 30 m × 0.25 mm × 0.25 mm (Phenomenex, Auck-
land, New Zealand) was connected into a Programmable
Temperature Vaporiser (PTV-1079) injector. The tem-
peratures of the injector, ion trap, manifold and transfer
line were 250, 200, 60 and 250°C, respectively. The oven
program commenced at 60°C for 2 minutes and was
raised to 250°C at a rate of 10°C/min, at which the tem-
perature was maintained for a further 2 minutes.
Helium flow was set at a constant rate of 1.2 ml/min.
The split vent was opened to a ratio of 1:50 after 1 min.
Initial full scan spectra were obtained with a mass to
charge (m/z) range of 40-650 utilising electron impact
(EI) (Figure 2). A change to chemical ionisation (CI)
with methanol as the precursor ion in full scan mode
increased sensitivity for 2-AA in comparison to EI.
In order to analyse 2-AA in breath it was necessary to
utilise the MS-MS capabilities of the ion trap due to
matrix and very low detection level requirements. Ion
preparation for MS-MS analysis was in CI mode; the
selected parent ion was m/z 135 with an isolation win-
dow of m/z 3; excitation storage level was 65; excitation
amplitude was 48; the resulting MS-MS spectra featured
three main peaks at m/z 118 (100%), m/z 136 (90%) and
m/z 94 (45%) (Figure 3). Further sensitivity was achieved
by additional fragmentation using MS
3. The selected
daughter ion was m/z 118 with an isolation window of
m/z 3; excitation storage level was 65; excitation ampli-
tude was 48; the resulting MS
3 spectra featured one
main peak at m/z 118 (100%) (Figure 4).
Figure 1 NIST library formula and mass spectra of 2-AA under EI conditions.
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Page 2 of 10Figure 2 Experimental spectra for 2-AA, obtained under GC/MS EI conditions, from in vitro Ps. aeruginosa cultures.
Figure 3 Experimental spectra for 2-AA, obtained under GC/MS-MS CI conditions, from in vitro Ps. aeruginosa cultures.
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The following species were tested; Ps. aeruginosa
(20 strains), E. coli (3 strains), Burkholderia multivorans
(3 strains), Haemophilus influenzae (3 strains), Legio-
nella pneumophila (3 strains), Moraxella catarrhalis
(3 strains), Pseudomonas fluorescens (3 strains), Staphy-
lococcus aureus (3 strains), Streptococcus pneumoniae
(3 strains) and Aspergillus fumigatus (3 strains). All
strains were isolated and identified from a variety of
respiratory specimens by Canterbury Health Labora-
tories, Christchurch, New Zealand by standard techni-
ques [15]. B. multivorans strains were identified by API
20 NE and 16S rRNA sequencing [16]. All strains were
stored at 4°C and re-plated regularly.
Culture methods
All micro-organisms were cultured in 50 ml screw top
bottles (Alltech Associates Inc. Illinois, United States of
America) containing 10 ml of medium. Columbia Sheep
Blood agar, Sheep Blood agar, and Mueller-Hinton agar
were purchased from Fort Richards Laboratories Ltd,
Auckland, New Zealand. Luria Bertani agar and M9
Minimal Media broth was prepared in the laboratory as
specified in the Handbook of Microbiological Media
[17]. The open screw cap contained a Teflon lined sili-
cone septa. Two replicates of each micro-organism
strain were inoculated into the media separately
(0.5 MacFarlane Standard). The bottles were sealed
tightly and incubated for at least 24 hours at 37°C, aero-
bically. The headspace gas was sampled using SPME by
penetrating the septum.
Drug testing for 2-AA
The agents were reconstituted into a glass vial with a
Teflon septum according to the manufacturer’sr e c o m -
mendations. The SPME fibre was introduced into the
headspace through the septum for 5 minutes and then
desorbed into the GC/MS instrument for analysis by full
scan and MS-MS.
Environmental air sampling
Levels of environmental 2-AA were determined from
two sites where breath samples were collected (Respira-
tory Ward and Out Patients at Christchurch Hospital,
New Zealand). Ten clean glass bulbs were prepared for
environmental air sampling with a vacuum of 550 mm
Hg. Bulbs were transported to sampling sites and the
stop cocks opened releasing the vacuum and in turn
sampling the environmental air. As soon as the sample
was obtained the stopcocks were closed and the bulbs
transported back to the laboratory for analysis. SPME
fibres were inserted via the septa within 30 minutes. All
sampling devices were incubated at 37°C for 24 hours
before analysis.
Figure 4 Experimental spectra for 2-AA, obtained under GC/MS3 CI conditions, from a breath samples positive for 2-AA.
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Written informed consent was obtained from all sub-
jects. Control subjects were healthy, non-smoking adults
who had no known respiratory disease, and were not
taking prescription or over the counter medication. Sub-
jects (both adults and children) with clinically stable CF
were identified by staff of specialist respiratory services
at Christchurch Hospital, New Zealand. All subjects had
CF diagnosed either by genetic analysis or at least three
positive sweat tests (>60 mmol/L) and progressive
o b s t r u c t i v ea i r w a yd i s e a s ec h a racterised by a persistent,
productive cough, hyperinflation of the lung fields on
chest radiograph, and obstructive pulmonary function
tests. Computerised medical records were reviewed for
the past medical history and laboratory investigations
and the diagnoses were confirmed by a specialist
respiratory physicia n .C Fp a t i e n t sw i t hPs. aeruginosa
had to have at least two positive sputum and/or BALF
tests for Ps. aeruginosa for inclusion into this group.
The micro-organisms present in the respiratory secre-
tions of CF patients were identified by culture at Can-
terbury Health Laboratories, Christchurch, New
Zealand. A drug and dietary history was taken using a
standardised questionnaire and entered into a data
sheet.
Breath sampling
Sampling was done between 8.30-9.30 am or 1.30-
3.30 pm and the subjects food and/or fluid ingestion,
over the 12 hours prior to breath collection, was
recorded. Breath samples were obtained more than two
hours after consumption of any foods.
All healthy controls and subjects with CF were studied
in facilities sourced from a common air conditioning
system. No other filters or control systems were used.
Breath samples were collected by forced expiration of
five breaths into the 1 L silanized glass sampling bulb
without a nose clip or saliva trap. Stop cocks at each
end were opened while breath was collected by forced
expiration directly into the bulb without any additional
mouthpiece. Some rest was allowed between breaths but
all breath samples were collected within two minutes.
As soon as the breath samples were collected the stop
cocks were closed and the device was ready for analysis.
Collection bulbs were taken to the GC/MS laboratory
within 30 minutes of collection, SPME fibres were
inserted via the septa within two hours. All sampling
devices were incubated at 37°C for 24 hours before
analysis.
Statistical analysis
Degradation of 2-AA in the glass bulb was tested with
the I-test adapted for unequal variances. A five para-
meter log logistic (5PL) model was fitted to the data
and the EC50 estimated using the R package drc [18].
The 5PL model may be parameterised by equation 1
where c and d are the minimum and maximum concen-
trations respectively, d the hill slope, e the EC50 and f
the asymmetry parameter.
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The four parameter log logistic (4PL) model has the
same parameterisation as the 5PL with f set to 1, forcing
symmetry about the point of inflection. ANOVA shows
that the 5PL had significantly better fit to the data than
the 4PL model (p < 0.0002). The estimated minimum
concentration for the 5PL model was -3.18 (SE 8.99)
hence we fitted a 5PL model with the minimum concen-
tration, c, constrained to 0 to aid interpretability. Table 1
shows the Akaike Information Criterion (AIC) for each
model and the estimated ECp where the 95% confidence
intervals were estimated by the delta method [18]. The
AIC is a measure of fit which penalises additional para-
meters; lower values indicate better fit so the table shows
that the 5PL model fits better than the 4PL while fixing
the minimum concentration provides a marginal
improvement. The colonised subjects were compared
with both control groups for presence versus absence
(below threshold of 2-AA detection) in breath with
Fisher’s exact test. The Mann-Whitney test was used to
compare the peak integration values of the three group’s
breath tested. Statistical tests and modelling was per-
formed in R version 2.10 [19].
Ethical approval
E t h i c a la p p r o v a lf o rt h es t u d yw a so b t a i n e df r o mt h e
Upper South Island Ethics Committee, New Zealand
and the study was conducted in accordance with the
standards for clinical research of the University of
Otago, New Zealand.
Results
2-AA production by bacteria in vitro
Twenty clinical isolates of Ps. aeruginosa (including 12
mucoid strains) obtained from a variety of respiratory
samples submitted to Canterbury Health Laboratories
were tested. 2-Aminoacetophenone was detected in the
Table 1 2-AA degradation models
Model AIC EC50 95% CI
5PL c = 0 144.84 11.73 10.94 12.52
5PL 146.48 12.38 9.03 15.73
4PL 162.30 9.71 8.92 10.49
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range) in all isolates after 24 hours incubation on Sheep
Blood agar. 2-Aminoacetophenone was detected 10 out
of 10 times from the head space of a single Ps. aerugi-
nosa strain cultured on Columbia Sheep Blood agar.
This same strain also produced 2-AA when cultured on
Mueller-Hinton agar, Luria Bertani agar, M9 Minimal
Media broth and laboratory tap water. 2-Aminoaceto-
phenone was not detected from the head space of
H. influenzae, L. pneumophila, M. multivorans, Ps. fluor-
escens, B. multivorans, S. pneumoniae and A. fumigatus
strains upon culturing on Columbia Sheep Blood agar,
Sheep Blood agar and Mueller-Hinton agar. S. aureus
and E. coli strains did not produce 2-AA when grown
on Sheep Blood agar or Mueller-Hinton agar. However,
one out of three S. aureus strains and two out of three
E. coli strains produced trace levels of 2-AA (low pico
mol/mol) on Columbia Sheep Blood agar.
2-AA stability in breath collection systems
2 L Tedlar® bags and 1 L deactivated glass bulbs were
spiked (10 μmol) with 2-AA reference standard and
were analysed for stability of 2-AA at 37°C. Within two
hours of spiking, only 10% of the initial concentration
was detectable in the Tedlar® bags and no 2-AA was
detectable after 24 hours. 2-Aminoacetophenone was
found to be stable over two hours in the glass sampling
bulb and after 24 hours approximately 40% was still pre-
sent. The preliminary comparison showed the superior-
ity of the glass sampling bulbs for 2-AA. To determine
the “half-life” of 2-AA in the glass sampling bulb system,
2-AA was spiked into the glass bulbs (three replicates)
at a concentration of 10 μmol. The resulting time degra-
dation is illustrated in Figure 5. The EC50 for 2-AA was
estimated to be 11.73 hours (95% CI 10.94, 12.52).
A peak integration area of 88 was determined as the
lower limit of detection (detection limit) for 2-AA in the
1 L glass sampling bulb filled with ambient air. This
peak integration value was determined to be a concen-
tration 50 pmol/mol (n = 15 with a standard deviation
of 4.8 pmol/mol).
Environmental air sampling
Air samples were analysed from the two collection sites
in MS
3 mode to ensure no environmental contamina-
tion of breath samples with 2-AA. The levels of 2-AA
detected in the environmental samples were well below
the threshold of detection in all samples analysed from
both sites.
Study population
The clinical characteristics, medication use and micro-
organisms isolated from CF sputum samples are shown
in Tables 2, 3 and 4. As expected, subjects colonised
with Ps. aeruginosa were associated with older age,
more complications of CF with more anti-pseudomonal
and antimicrobial therapy. S. aureus colonisation was
more frequent in those who were not colonised with Ps.
aeruginosa 11/13 (85%) compared to those that were
colonised with Ps. aeruginosa 7/16 (43%). Food and
fluid intake in the previous 12 hours was similar in both
the subject and the control group (Table 5).
Detection of 2-AA in breath samples
The 2-AA was detected in a significantly higher propor-
tion of subjects colonised with Ps. aeruginosa 15/16
(93.7%) than both the healthy controls 5/17 (29%) (p <
0.0002) and CF patients not colonised with Ps. aerugi-
nosa 4/13 (30.7%) (p < 0.001). The sensitivity and speci-
ficity of the 2-AA breath test compared to isolation of
Ps. aeruginosa in sputum and/or BALF was 93.8% (95%
CI, 67-99) and 69.2% (95% CI, 38-89) respectively. The
peak integration values for 2-AA analysis in the breath
samples are shown in Figure 6. These values were signif-
icantly higher in the breath of patients colonised with
Ps. aeruginosa (median 242, range 0-1243) than the
healthy controls (median 0, range 0-161; p < 0.001) and
CF subjects not colonised with Ps. aeruginosa (median 0,
range 0-287; p < 0.003).
Discussion
There is well-established and growing interest in the
detection and identification of micro-organisms by mea-
suring their release of volatile organic compounds
(VOCs) [20]. Because 2-AA is associated with the
“grape-like” smell of Ps. aeruginosa and is more consis-
tently produced than the common pyocyanin [21], it
was hypothesized that 2-AA could be a potential breath
Figure 5 A time degradation graph of 2-AA in glass sampling
bulbs. The 2-AA levels (mean and SD) from three replicate
experiments are shown and a five parameter logistic function fitted
to the degradation curve (11.73 hours (95% CI 10.94, 12.52). 2-AA
levels at 8 and 10 hours were significantly less (P < 0.001) than four
and six hours.
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Page 6 of 10Table 2 Characteristics of subjects included in breath sampling
Healthy controls CF - Ps. aeruginosa colonised CF - Ps. aeruginosa non-colonised
Number (n) 17 16 13
Age years (mean range) 38 (25-54) 26.9 (13-59) 14.9 (6-43)
Male (%) 38% 63% 53%
BMI (kg/m
2) (mean range) 19.07 (17.1-24.4) 19.9 (14.8-37.2)
Respiratory function: FEV1% 44.92 (13-93) 77.15 (48-99)
FVC% 59.51 (1.14-102) 91.1 (55-120)
Genetic analysis Sweat test (3) Sweat test (3)
ΔF508/ΔF508 (9) ΔF508/ΔF508 (5)
ΔF508/G542X (3) ΔF508/G542X (1)
ΔF508/c.1339delA (1) c.F508/c.1766+1g (1)
ΔF508/3849+10kbct (1)
c.1624g > t(p.g542x)/c.1
624g > t(p.g542x) (1)
ΔF508/P67L (1)
Diagnoses
^
Pancreatic insufficiency 15 12
Chronic rhinosinuitis 9 0
Osteopenia 8 0
Gastro-oesophageal disease 7 0
CF related diabetes 4 3
Vitamin A, D & E deficiency 5 1
Asthma 5 0
Allergic bronchopulmonary 0 3
aspergillosis
Distal intestinal obstruction 1 2
syndrome
Previous tuberculosis 1 0
Pancreatitis 1 0
Chronic nasal polyps 0 1
Haemoptysis 0 0
Chronic eczema & ichthyosis 1 1
^Some CF subjects had multiple diagnoses
Table 3 Medication prescribed to cystic fibrosis patients at time of breath sampling*
Medication CF - Ps. aeruginosa colonised (n = 16) CF - Ps. aeruginosa non-colonised (n = 13)
Creon® 8 13
Tobramycin nebulised 9 1
Colistin nebulised 7 1
Fluticasone propionate 3 5
Salbutamol 4 4
Budesonide-formoterol 4 3
Itraconazole 2 5
Dornase alfa 3 1
Budesonide 3 0
Ciprofloxacin 0 3
Salmeterol 2 0
Beclomethasone 2 0
Vancomycin 1 0
Formoterol fumarate 1 0
Amphotericin B 0 1
* All CF subjects were taking multiple medications
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Page 7 of 10biomarker for Ps. aeruginosa growth in the CF lung. We
have confirmed that Ps. aeruginosa consistently pro-
duces 2-AA during in vitro growth on several types of
media. Our analytical GC/MS technique also detected
trace amounts of 2-AA in two of the three E. coli strains
tested and in one of the three S. aureus strains, how-
ever, the level was two magnitudes lower than the 2-AA
levels detected in Ps. aeruginosa cultures. Although Ps.
aeruginosa produces millimol levels of 2-AA in ideal
aerobic conditions, we have yet to determine whether
2-AA production is dependent on the growth phase of
the organisms or if it is affected by oxygen tension or
nutrient supply. It is possible these conditions will differ
between early lung colonisation and established Ps. aer-
uginosa infection, potentially affecting the performance
of a breath test.
Our breath sampling system involves the collection of
breath into a transportable device. Here, preliminary
data showed that significant levels of background emis-
sions from the Tedlar® bag itself (even after N2 flushing)
do interfere with the 2-AA detection. Even in the deacti-
vated glass sampling bulb 2-AA does not remain stable
due to its reactive, polar chemical nature (11.73 hours
(95% CI 10.94, 12.52)). 2-Aminoacetophenone is thought
to undergo oxidation to 2-nitroacetophenone but can be
analysed accurately provided breath samples are pro-
cessed promptly. A five parameter logistic function was
fitted to the degradation data (Figure 5) and used to
estimate EC50. Such models do not assume symmetry
and it has been shown that any function with less than
five parameters is unlikely to have the flexibility neces-
sary to produce a high-quality fit to asymmetric sigmoi-
dal dose-response data [22].
The analysis of specific markers for infectious diseases
in breath is difficult due to the very low levels of volatiles
present in the breath matrix [23,24]. However, GC/MS
3
is a very sensitive technique and coupled with SPME pre-
concentration extremely low levels of analytes can be
detected. Comparing spiked samples (ambient air spiked
with the 2-AA reference standard) with real breath sam-
ples can be used for an assessment of a detection range
provided the same experimental procedure is followed.
The most important finding of this study was that
2-AA was present above the limit of detection in a
Table 4 Micro-organism isolated from sputum of patients with cystic fibrosis
#
Organism CF - Ps. aeruginosa colonised CF - Ps. aeruginosa non-colonised
(n = 16) (n = 13)
Pseudomonas aeruginosa 16 0
Staphylococcus aureus 71 1
Aspergillus fumigatus 62
Haemophilus influenzae 08
Oropharyngeal flora 5 3
Candida species 1 2
Burkholderia multivorans 02
Inquilinus limosus 10
Penicillium species 0 1
Stenotrophomonas maltophilia 01
Scedosporium apiospermum 10
Wangiella dermatitidis 10
# All CF subjects had multiple micro-organisms in the lung
Table 5 Survey of food consumption prior to 12 hours of breath collection
Food Healthy controls (n = 17) CF - Ps. aeruginosa colonised (n = 16) CF - Ps. aeruginosa non-colonised (n = 13)
Milk 10 7 9
Cheese 1 2 0
Energy Drink 1 2 2
Coffee 6 3 1
Yoghurt 2 4 1
Green tea 0 1 0
Beer 0 0 0
Sweet corn 0 0 0
Corn chips 0 1 1
Honey 0 2 0
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were colonised with Ps. aeruginosa, than both control
groups (Figure 6). The peak integration values of 2-AA
can be regarded as semi-quantitative only, but are con-
sistent with the results of the analysis for presence or
absence of 2-AA in breath, and support the conclusion
that the likely source of the 2-AA are Ps. aeruginosa
colonising the lungs. In contrast there was no evidence
that S. aureus colonisation of the lung produced a posi-
tive 2-AA breath test despite trace amounts being
detectable in the headspace of in vitro cultures. This
preliminary study supports the concept that 2-AA may
potentially serve as a biomarker of pseudomonas infec-
tion or colonisation in CF patients. This is consistent
with previous studies of Aspergillus colonisation and
Mycobacterium tuberculosis infection showing that spe-
cific biomarkers of these organisms are detectable in the
breath by GC/MS techniques [24-26]. 2-Aminoaceto-
phenone was also detectable in a small proportion of
both healthy controls and subjects with CF who did not
have evidence of Ps. aeruginosa on sputum sampling.
The levels of 2-AA were very low and the origins of this
signal are, at present, unknown.
As with any breath test, food, environment and medi-
cation are potential sources of the diagnostic marker.
2-Aminoacetophenone has been reported in foods and
beverages namely corn, dairy, honey products and wine
[27-29]. Breath testing immediately after the consump-
tion of any one of these products may potentially give a
false positive result. Investigation into whether ingested
2-AA rich food and beverages may increase 2-AA levels
in the breath is currently ongoing. While ingested 2-AA
may reach the breath it is possible that some or all may
be metabolised by the host. It is not known whether
prescribed or over the counter medication may also arti-
ficially increase or decrease the levels of 2-AA found in
the breath but we have tested clinical preparations of
tobramycin and colistin to exclude these as a potentially
confounding source of 2-AA in this study. It is possible
that some medications may breakdown to 2-AA which
will require detailed investigations given the wide variety
of medication taken by CF sufferers. A further possible
source of 2-AA, particularly in CF patients is microbial
colonisation of the mouth which was not detected on
the sputum sampling. This may come from oral flora as
well as Ps. aeruginosa. Further studies are needed to
exclude these possible sources and it may be possible to
reduce 2-AA levels in healthy individuals by careful con-
trol of the experimental conditions.
One of the major problems with breath testing in gen-
eral is the sampling technique. Only a small number of
studies have been performed to investigate the factors that
affect the concentration of endogenous VOC’so nt h e
breath before it exits the mouth [30]. While deactivated
glass bulbs have been used successfully in previous studies
[24-26] the most appropriate breath sampling technique
for microbial derived VOCs has not yet been determined.
Conclusions
In conclusion our investigation supports the concept that
2-AA is a potential breath biomarker for Ps. aeruginosa
and warrants further investigation as an indicator of Ps.
aeruginosa colonisation or infection in the CF lung.
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